Show simple item record

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

dc.contributor.authorFRANZ, David N.
dc.contributor.authorYapici, Zühal
dc.contributor.authorPELOV, Diana
dc.contributor.authorFrench, Jacqueline A.
dc.contributor.authorLawson, John A.
dc.contributor.authorIkeda, Hiroko
dc.contributor.authorPolster, Tilman
dc.contributor.authorNobbout, Rima
dc.contributor.authorCuratolo, Paolo
dc.contributor.authorde Vries, Petrus J.
dc.contributor.authorDiugos, Dennis J.
dc.contributor.authorBerkowitz, Noah
dc.contributor.authorVOI, Maurizio
dc.contributor.authorPEYRARD, Severine
dc.date.accessioned2021-03-02T23:18:42Z
dc.date.available2021-03-02T23:18:42Z
dc.date.issued2016
dc.identifier.citationFrench J. A. , Lawson J. A. , Yapici Z., Ikeda H., Polster T., Nobbout R., Curatolo P., de Vries P. J. , Diugos D. J. , Berkowitz N., et al., "Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study", LANCET, cilt.388, sa.10056, ss.2153-2163, 2016
dc.identifier.issn0140-6736
dc.identifier.othervv_1032021
dc.identifier.otherav_11be8da4-5afb-4e1f-a72b-2d3dff35fbaf
dc.identifier.urihttp://hdl.handle.net/20.500.12627/17382
dc.identifier.urihttps://doi.org/10.1016/s0140-6736(16)31419-2
dc.description.abstractBackground Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used for various benign tumours associated with tuberous sclerosis complex. We assessed the efficacy and safety of two trough exposure concentrations of everolimus, 3-7 ng/mL (low exposure) and 9-15 ng/mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in tuberous sclerosis complex.
dc.language.isoeng
dc.subjectTemel Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleAdjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
dc.typeMakale
dc.relation.journalLANCET
dc.contributor.departmentNHO Epilepsy Ctr , ,
dc.identifier.volume388
dc.identifier.issue10056
dc.identifier.startpage2153
dc.identifier.endpage2163
dc.contributor.firstauthorID52739


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record